Clinical Trials Browser

Interventional × urelumab × Other hematologic neoplasm × Clear all

NCT02420938 2016-12-06

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell